tiprankstipranks
Arcutis Biotherapeutics reports Q1 EPS (32c), consensus (73c)
PremiumThe FlyArcutis Biotherapeutics reports Q1 EPS (32c), consensus (73c)
25d ago
Arcutis Biotherapeutics options imply 12.9% move in share price post-earnings
PremiumThe Fly
Arcutis Biotherapeutics options imply 12.9% move in share price post-earnings
25d ago
Arcutis Biotherapeutics announces the JCAD published outcomes of ZORYVE
PremiumThe Fly
Arcutis Biotherapeutics announces the JCAD published outcomes of ZORYVE
27d ago
Arcutis Appoints David Topper as Chief Financial Officer
PremiumPress ReleasesArcutis Appoints David Topper as Chief Financial Officer
2M ago
Arcutis Biotherapeutics appoints David Topper as CFO
PremiumThe Fly
Arcutis Biotherapeutics appoints David Topper as CFO
2M ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2M ago
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
PremiumPress ReleasesNew Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
3M ago
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
PremiumPress Releases
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
3M ago
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
PremiumPress Releases
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100